• 1
    Knapp DW. Tumors of the urinary system. In: Withrow SJ, Vail DM, eds. Withrow and MacEwen's Small Animal Clinical Oncology, 4th ed. Philadelphia, PA: WB Saunders; 2007:649659.
  • 2
    Henry CJ, McCaw DL, Turnquist SE, et al. Clinical evaluation of mitoxantrone and piroxicam in a canine model of human invasive urinary bladder carcinoma. Clin Cancer Res 2003;9:906911.
  • 3
    Knapp DW, Glickman NW, Widmer WR, et al. Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer. Cancer Chemother Pharmacol 2000;46:221226.
  • 4
    Perazella MA, Moeckel GW. Nephrotoxicity from chemotherapeutic agents: Clinical manifestations, pathobiology, and prevention/therapy. Semin Nephrol 2010;30:570581.
  • 5
    Rao P, Knaus EE. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): Cyclooxygenase (COX) inhibition and beyond. J Pharm Pharm Sci 2008;11:81s110s.
  • 6
    Dhawan D, Jeffreys AB, Zheng R, et al. Cyclooxygenase-2 dependent and independent antitumor effects induced by celecoxib in urinary bladder cancer cells. Mol Cancer Ther 2008;7:897904.
  • 7
    Khan KN, Knapp DW, Denicola DB, et al. Expression of cyclooxygenase-2 in transitional cell carcinoma of the urinary bladder in dogs. Am J Vet Res 2000;61:478481.
  • 8
    Harirforoosh S, Jamali F. Renal adverse effects of nonsteroidal anti-inflammatory drugs. Expert Opin Drug Saf 2009;8:669681.
  • 9
    Greene SN, Ramos-Vara JA, Craig BA, et al. Effects of cyclooxygenase inhibitor treatment on the renal toxicity of cisplatin in rats. Cancer Chemother Pharmacol 2010;65:549556.
  • 10
    Suddek GM, El-Kenawi AE, Abdel-Aziz A, et al. Celecoxib, a selective cyclooxygenase-2 inhibitor, attenuates renal injury in a rat model of cisplatin-induced nephrotoxicity. Chemotherapy 2011;57:321326.
  • 11
    Yamamato E, Izawa T, Sawamoto O, et al. Amelioration of cisplatin-induced rat renal lesions by a cyclooxygenase (COX)-2 selective inhibitor. Exp Toxicol Pathol 2012;64:625631.
  • 12
    Arúajo AM, Mendez JC, Coelho AL, et al. Phase II study of celecoxib with cisplatin plus etoposide in extensive-stage small cell lung cancer. Cancer Invest 2009;27:391396.
  • 13
    Autefage A, Palissier FM, Asimus E, et al. Long-term efficacy and safety of firocoxib in the treatment of dogs with osteoarthritis. Vet Rec 2011;168:617.
  • 14
    Joubert KE. The effects of firocoxib (Previcox) in geriatric dogs over a period of 90 days. J S Afr Vet Assoc 2009;80:179184.
  • 15
    Owen LN. TNM Classification of Tumors in Domestic Animals, 1st ed. Geneva: World Health Organization; 1980:34.
  • 16
    Chun R, Knapp DW, Widmer WR, et al. Phase II clinical trial of carboplatin in canine transitional cell carcinoma of the urinary bladder. J Vet Intern Med 1997;11:279283.
  • 17
    Veterinary C-OOG. Veterinary co-operative oncology group- Common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Comp Oncol 2004;2:194213.
  • 18
    Mohammed SI, Bennett PF, Craig BA, et al. Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res 2002;62:356358.
  • 19
    D D, Craig BA, Cheng L, et al. Effects of short-term celecoxib treatment in patients with invasive transitional cell carcinoma of the urinary bladder. Mol Cancer Ther 2010;9:13711377.
  • 20
    Khan Z, Khan N, Tiwari RP, et al. Biology of cox-2: An application in cancer therapeutics. Curr Drug Targets 2011;12:10821093.
  • 21
    Köberle B, Tomicic MT, Usanova S, et al. Cisplatin resistance: Preclinical findings and clinical implications. Biochim Biophys Acta 2010;1806:172182.
  • 22
    McMillan SK, Boria P, Moore GE, et al. Antitumor effects of deracoxib treatment in 26 dogs with transitional cell carcinoma of the urinary bladder. J Amer Vet Med Assoc 2011;239:10841089.
  • 23
    Knapp DW, Glickman NW, DeNicola DB, et al. Naturally-occurring canine transitional cell carcinoma of the urinary bladder: A relevant model of human invasive bladder cancer. Urol Oncol 2000;5:4759.